Analyst Research

Report Title Price
Provider: New Constructs, LLC
$25.00
Provider: Stock Traders Daily
$20.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Biomarin Pharmaceutical Inc Reaffirms FY 2013 Guidance-Conference Call


Thursday, 23 May 2013 09:00am EDT 

Biomarin Pharmaceutical Inc announced that for fiscal 2013, it expects total revenues in $530 million to $555 million range, expects GAAP loss forecast of $170 million to $195 million and non-GAAP adjusted EBITDA (loss) $(75) to $(50) million. According to I/B/E/S Estimates, analysts on an average were expecting the Company to report revenue of $556 million and net income of $(174) million for fiscal 2013. 

Related Company News

Company Quote

73.22
0.22 +0.30%
30 Sep 2014